- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00072436
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
A Phase I Trial of Gemcitabine Followed by a Short Infusion of Flavopiridol in Patients With Solid Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose of gemcitabine and flavopiridol in patients with solid tumors.
SECONDARY OBJECTIVES:
I. Determine the safety profile and toxic effects of this regimen in these patients.
II. Determine the pharmacokinetics of flavopiridol with and without gemcitabine in these patients.
III. Determine, using pharmacodynamic assays, the activity of flavopiridol as a cdk inhibitor in these patients.
IV. Determine, using pharmacodynamic assays, the markers of this regimen in these patients.
OUTLINE: This is a dose-escalation, multicenter study.
Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose.
Patients are followed at 30 days after study completion.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infection
- No severe malnutrition
No more than 2 prior chemotherapy regimens:
- Prior combined modality therapy (e.g., full-dose chemotherapy with radiosensitizing chemotherapy and radiotherapy) is considered 1 prior regimen if all therapy was delivered as part of 1 comprehensive treatment plan
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No other concurrent chemotherapy
- At least 6 months since prior radiotherapy to the lung parenchyma or mediastinum and no evidence of radiation pneumonitis on chest CT scan
- At least 4 weeks since other prior radiotherapy and recovered
- No prior radiotherapy to more than 50% of marrow volume
- No concurrent radiotherapy
- Histologically confirmed solid tumor for which gemcitabine is a treatment option OR for which no efficacious therapy exists
Must meet criteria for 1 of the following:
Measurable disease:
- At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
Nonmeasurable disease, including any of the following:
- Small lesions (less than 20 mm by conventional techniques OR less than 10 mm by spiral CT scan)
- Bone lesions
- Cytologically positive pleural or peritoneal disease
- Elevated tumor markers (e.g., carcinoembryonic antigen, CA 125, CA 19-9, or other tumor marker)
- Multinodular or confluent nonmeasurable pulmonary, hepatic, adrenal, intra-abdominal, or skin metastases
- No active CNS metastases
- Previously treated CNS metastases must be stable with no symptoms for 4 weeks after completion of treatment AND patient must be off steroid therapy or on a stable dose for at least the past 2 weeks
- No known leptomeningeal metastases
Performance status:
- ECOG 0-1
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm3;
- Platelet count at least 100,000/mm3
Hepatic:
- Bilirubin no greater than 1.5 mg/dL;
- SGOT no greater than 2.5 times upper limit of normal
Renal:
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 50 mL/min
Cardiovascular:
None of the following within the past 6 months:
- Myocardial infarction;
- Unstable angina;
- Transient ischemic attack;
Cerebrovascular accident
- No new cardiac arrhythmia possibly related to cardiac ischemia;
- No large and potentially symptomatic pericardial effusion;
- No cardiac disease that would preclude study participation
Pulmonary:
- No pulmonary embolism within the past 6 months;
- No large and potentially symptomatic pleural effusion;
- No pulmonary disease that would preclude study participation
Gastrointestinal:
- No intractable emesis;
- No grade 2 or greater chronic diarrheal disease within the past 6 months
- Not pregnant or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose. |
Given IV
Other Names:
Correlative studies
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose-limiting toxicity (DLT) graded by National Cancer Institute (NCI) Common Toxicity Criteria
Time Frame: 28 days
|
28 days
|
Maximum tolerated dose, defined as one dose level below the dose that induces DLT in more than 1/6 patients
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Geoffrey Shapiro, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Gemcitabine
- Alvocidib
Other Study ID Numbers
- NCI-2009-00038
- U01CA062490 (U.S. NIH Grant/Contract)
- P30CA006516 (U.S. NIH Grant/Contract)
- 6051
- CDR0000339727 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on alvocidib
-
National Cancer Institute (NCI)CompletedLymphoma | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedEndometrial CancerUnited States, Canada, Norway, United Kingdom, Australia
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedLymphomaUnited States
-
Sumitomo Pharma America, Inc.TerminatedAcute Myeloid Leukemia (AML)United States
-
NCIC Clinical Trials GroupCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
National Cancer Institute (NCI)Completed
-
NCIC Clinical Trials GroupCompletedSarcomaCanada, United States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedLeukemiaUnited States